Business Context and Reporting Period
Company: DexCom, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems. Key products include the G7 system, the G7 15 Day system (launched late 2025), and Stelo (an over-the-counter biosensor launched in August 2024).
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $1,308.4 | $2,500.3 |
| Gross Profit | $830.0 | $1,580.3 |
| Gross Margin | 63.4% | 63.2% |
| Operating Income | $318.3 | $573.6 |
| Net Income | $249.1 | $448.6 |
| Diluted EPS | $0.64 | $1.15 |
| Operating Cash Flow | N/A | $794.8 |
| Cash & Short-term Investments | $1,947.0 (Total) | $1,947.0 (Total) |
| Long-term Debt | $1,242.8 | $1,242.8 |
Note: Cash and short-term marketable securities totaled $1.95 billion as of June 30, 2026 ($1,105.0 million cash + $842.0 million short-term securities).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13% year-over-year (YoY) for the quarter and 14% YoY for the six-month period. Growth was driven by increased sales volume of disposable sensors and favorable revenue per customer due to payor mix and utilization.
- Profitability Expansion: Operating income surged 50% YoY for the quarter and 66% YoY for the six-month period. Gross margin improved to 63.4% (Q2 2026) from 59.5% (Q2 2025), aided by manufacturing efficiencies and the G7 15 Day product mix.
- Inventory Charges: The company recorded inventory reserve charges of $45.6 million in Q2 2026 (vs. $8.8 million in Q2 2025) and $84.2 million for the six months (vs. $37.0 million), primarily due to the planned discontinuation of G6 manufacturing.
- Other Income: Other income (expense), net decreased significantly due to lower interest/dividend income and net losses on equity investments ($10.0 million loss in Q2 2026).
Guidance, Outlook, and Risks
- Share Repurchases: In May 2026, the Board authorized a new $1.00 billion share repurchase program (2026 Program), terminating the prior program with $250 million remaining. The company repurchased 8.6 million shares for $600.0 million in the first six months of 2026 under the new program.
- Product Outlook: Management continues to invest in R&D for intelligent insulin administration and networked platforms. The company expects to add 600,000 to 700,000 net customers annually (excluding Stelo).
- Liquidity: The company maintains a strong liquidity position with $1.95 billion in cash and equivalents. It has a $200 million revolving credit facility with $191.3 million available as of June 30, 2026.
- Legal Contingencies: Significant litigation risks include:
- Securities Class Actions: Ongoing proceedings regarding alleged false statements on revenue expectations and G7 device functionality. Motions to dismiss are pending or partially granted.
- Product Liability: Consolidated class actions alleging G6/G7 devices were adulterated, misbranded, or failed to perform as advertised.
- Tax Rate: The estimated annual effective tax rate for 2026 is 21.8%, lower than the prior year due to the commencement of a Malaysia tax holiday.
Investor Verification Checklist
- Inventory Reserves: Verify the magnitude of inventory write-downs related to the G6 discontinuation and the impact on future cost of sales.
- Legal Exposure: Monitor the status of the securities class actions and G6/G7 product liability suits, as outcomes could result in material financial adjustments.
- Share Repurchase Execution: Track the pace of the new $1.0 billion buyback program and its impact on share count and EPS.
- Customer Growth: Confirm the reported addition of 600,000–700,000 net customers and the mix of G7 vs. Stelo adoption.
- Debt Conversion: Review the terms of the $1.25 billion senior convertible notes due 2028, specifically conversion triggers that could dilute shareholders.